Vincent Servois

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 596 citations

Oncology, Neoadjuvant Therapy, Anti-pd-1/pd-l1 Therapy +6

Novel patterns of response under immunotherapy

Édith Borcoman, Yada Kanjanapan, Stéphane Champiat et al. · Annals of Oncology · 2019 · 491 citations · Full text

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Carotid and vertebral artery dissections: three-dimensional time-of-flight MR angiography and MR imaging versus conventional angiography.

C.D.P. Levy, Jean‐Pierre Laissy, V. Raveau et al. · Radiology · 1994 · 382 citations